CN107006857A - 一种调节免疫功能的保健食品及其制备方法 - Google Patents
一种调节免疫功能的保健食品及其制备方法 Download PDFInfo
- Publication number
- CN107006857A CN107006857A CN201710253682.0A CN201710253682A CN107006857A CN 107006857 A CN107006857 A CN 107006857A CN 201710253682 A CN201710253682 A CN 201710253682A CN 107006857 A CN107006857 A CN 107006857A
- Authority
- CN
- China
- Prior art keywords
- health food
- immunologic function
- extract
- function
- health
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000036737 immune function Effects 0.000 title claims abstract description 44
- 235000013402 health food Nutrition 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 238000001035 drying Methods 0.000 claims abstract description 15
- 239000011248 coating agent Substances 0.000 claims abstract description 6
- 238000000576 coating method Methods 0.000 claims abstract description 6
- 238000012946 outsourcing Methods 0.000 claims abstract description 6
- 238000012856 packing Methods 0.000 claims abstract description 6
- 235000020985 whole grains Nutrition 0.000 claims abstract description 6
- 238000005453 pelletization Methods 0.000 claims abstract description 5
- 239000007788 liquid Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 235000013361 beverage Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000000284 extract Substances 0.000 abstract description 31
- 240000004507 Abelmoschus esculentus Species 0.000 abstract description 20
- 230000033228 biological regulation Effects 0.000 abstract description 19
- 235000003934 Abelmoschus esculentus Nutrition 0.000 abstract description 15
- 238000000605 extraction Methods 0.000 abstract description 15
- 235000008434 ginseng Nutrition 0.000 abstract description 14
- 239000000843 powder Substances 0.000 abstract description 14
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 abstract description 13
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract description 13
- 240000000759 Lepidium meyenii Species 0.000 abstract description 12
- 235000000421 Lepidium meyenii Nutrition 0.000 abstract description 12
- 235000012902 lepidium meyenii Nutrition 0.000 abstract description 12
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract description 10
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract description 10
- 235000021511 Cinnamomum cassia Nutrition 0.000 abstract description 9
- 239000009429 Ginkgo biloba extract Substances 0.000 abstract description 7
- 229940068052 ginkgo biloba extract Drugs 0.000 abstract description 7
- 235000020686 ginkgo biloba extract Nutrition 0.000 abstract description 7
- 238000003860 storage Methods 0.000 abstract description 6
- 241001264174 Cordyceps militaris Species 0.000 abstract description 3
- 231100000252 nontoxic Toxicity 0.000 abstract description 3
- 230000003000 nontoxic effect Effects 0.000 abstract description 3
- -1 sealwort Substances 0.000 abstract description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 241001521901 Tribulus lanuginosus Species 0.000 abstract 1
- 238000010298 pulverizing process Methods 0.000 abstract 1
- 238000007873 sieving Methods 0.000 abstract 1
- 239000000047 product Substances 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 230000006870 function Effects 0.000 description 17
- 230000036541 health Effects 0.000 description 16
- 241001533104 Tribulus terrestris Species 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 244000194101 Ginkgo biloba Species 0.000 description 13
- 240000004371 Panax ginseng Species 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 11
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 10
- 235000008100 Ginkgo biloba Nutrition 0.000 description 10
- 230000036039 immunity Effects 0.000 description 10
- 241000522254 Cassia Species 0.000 description 9
- 235000011201 Ginkgo Nutrition 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 210000004698 lymphocyte Anatomy 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 240000008397 Ganoderma lucidum Species 0.000 description 7
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 7
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 230000000242 pagocytic effect Effects 0.000 description 6
- 108010006464 Hemolysin Proteins Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 208000026935 allergic disease Diseases 0.000 description 5
- 230000007815 allergy Effects 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 239000003228 hemolysin Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 5
- 229930182490 saponin Natural products 0.000 description 5
- 150000007949 saponins Chemical class 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 244000080208 Canella winterana Species 0.000 description 4
- 235000008499 Canella winterana Nutrition 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- MUKYLHIZBOASDM-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid 2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound NC(=N)N(C)CC(O)=O.OCC(O)C(O)C(O)C(O)C(O)=O MUKYLHIZBOASDM-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 241000238370 Sepia Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000007969 cellular immunity Effects 0.000 description 3
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 3
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000004727 humoral immunity Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000001539 phagocyte Anatomy 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000004537 pulping Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 241000255789 Bombyx mori Species 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 241000190633 Cordyceps Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000222336 Ganoderma Species 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- ZXVONLUNISGICL-UHFFFAOYSA-N 4,6-dinitro-o-cresol Chemical group CC1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O ZXVONLUNISGICL-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 244000283482 Alloteropsis cimicina Species 0.000 description 1
- 241000554155 Andes Species 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000038022 Chenopodium capitatum Species 0.000 description 1
- 235000004391 Chenopodium capitatum Nutrition 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000723347 Cinnamomum Species 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- OEKPKBBXXDGXNB-IBISWUOJSA-N Digitalose Natural products CO[C@H]1[C@@H](O)[C@@H](C)O[C@@H](O)[C@@H]1O OEKPKBBXXDGXNB-IBISWUOJSA-N 0.000 description 1
- 235000017898 Digitaria ciliaris Nutrition 0.000 description 1
- 241000086550 Dinosauria Species 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- RDMQPKIDHAFXKA-JNORPAGFSA-N Ganoderic Acid Am1 Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CC(=O)CC(C)C(O)=O)C)CC(=O)[C@]21C RDMQPKIDHAFXKA-JNORPAGFSA-N 0.000 description 1
- 229930182735 Ganoderic acid Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 241000976924 Inca Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000446313 Lamella Species 0.000 description 1
- 241000801118 Lepidium Species 0.000 description 1
- 101000874159 Mus musculus Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 241000756042 Polygonatum Species 0.000 description 1
- 235000008737 Polygonatum biflorum Nutrition 0.000 description 1
- 241000037826 Polygonatum kingianum Species 0.000 description 1
- 241000037831 Polygonatum sibiricum Species 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 240000000278 Syzygium polyanthum Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 241000159213 Zygophyllaceae Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000002019 anti-mutation Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- MPQBLCRFUYGBHE-JRTVQGFMSA-N digitalose Chemical compound O=C[C@H](O)[C@@H](OC)[C@@H](O)[C@@H](C)O MPQBLCRFUYGBHE-JRTVQGFMSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- YAGKRVSRTSUGEY-UHFFFAOYSA-N ferricyanide Chemical compound [Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] YAGKRVSRTSUGEY-UHFFFAOYSA-N 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004262 retinal health Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
本发明公开了一种调节免疫功能的保健食品及其制备方法,由玛咖、人参、灵芝孢子粉、蛹虫草、秋葵提取物、黄精、银杏提取物、刺蒺藜提取物、肉桂提取物。经过粉碎过筛→预混→制粒干燥→整粒→总混→压片→包衣→内包装→外包→入库制得。本发明安全,无毒性,可口服,口服或食用方便,有显著调节免疫功能保健功能。
Description
技术领域
本发明属于保健品领域,具体的说,涉及一种调节免疫功能的保健食品及其制备方法。
背景技术
免疫是人体的一种识别“自己”、排除“非己”成分的保护性功能,主要包括1)抵抗抗原的入侵;2)防止患病,及时清除体内衰老、死亡、损伤的细胞;3)随时识别和清除体内产生的异常细胞。免疫系统的组成包括免疫器官(骨髓、脾脏、胸腺,淋巴组织和扁桃腺);免疫细胞(B淋巴细胞和T淋巴细胞)以及免疫活性物质(抗体、白介素和干扰素等淋巴因子和溶菌酶)。
淋巴细胞是免疫系统的主要成员,存在于血液中,也存在于淋巴系统中。根据免疫功能的不同,淋巴细胞可分为B细胞和T细胞两类。B细胞大多集中在淋巴结等淋巴器官中,T细胞存在于淋巴结、脾脏等器官中,血液和淋巴中的淋巴细胞80%是T细胞,20%是B细胞。人体的淋巴细胞很多(约2×10鍄12个)且十分活跃,时刻在监视外物的入侵。它们能穿过毛细血管壁,活动于血液中,淋巴细胞除分布在淋巴及血管外,还分布在各组织细胞之间的组织液中。淋巴细胞的表面带有许多识别抗原的受体,即能和抗原结合的分子,所以它能和抗原结合。又由于不同的淋巴细胞表面带有不同的抗原受体分子,所以它能分别和不同的抗原分子结合,发生免疫反应。
免疫可分为非特异性免疫(先天性免疫)和特性免疫(后天性免疫二种),前者有皮肤,黏膜和体液中的杀菌物质和吞噬细胞组成,构成了人体的第一和第二道防线;后者有T和B淋巴细胞组成,包括体液免疫和细胞免疫,构成了人体的第三道防线。
当免疫功能正常时,可以发挥监视和清除功能:监控和清除体内已经衰老或因其他因素而被破坏的细胞,以及癌变的细胞,保存机体的正常运转。当免疫功能过高时,可形成自身免疫性疾病或过敏反应,其后者的特点是发展迅速、反应强烈、消退较快;一般不会破坏组织细胞,也不会引起组织严重损伤;有明显的倾向和个体差异;当免疫功能过低时,可形成先天免疫缺陷性疾病、艾滋或肿瘤。
基于此,需要找到调节免疫功能物质来保证免疫功能的正常,预防或纠正免疫功能的低下或过敏变态反应造成的免疫性疾病,或通过免疫的调节来预防疾病的发生,延缓疾病的进程,加速疾病的康复等,以期使人们从疾病状态或亚健康状态恢复正常。现有的调节免疫功能本保健食品主要以中药为主,特点是注重养生,消费者需长期服用,起效慢。
因此,提供一种新的调节免疫功能产品具有现实意义。
发明内容
为解决以上技术问题,本发明的目的之一在于提供一种起效快,显著调节免疫功能的保健品。
本发明的目的之二在于提供一种起效快,显著调节免疫功能的保健品制备方法。
本发明目的之一是这样实现的:
一种调节免疫功能的保健食品,按重量份数包含以下组分:
上述保健食品还添加有药用辅料。
上述保健食品为口服液、饮料、片剂、胶囊、喷雾剂或透皮吸收剂。本保健食品的给药方式为口服或外用。所述本保健食品的服用方式为每日1~2次,每次1000-3000mg/60kg体重。
本发明目的之二是这样实现的:
一种调节免疫功能的保健食品的制备方法,按如下步骤进行:原辅料粉碎过筛→预混→制粒干燥→整粒→总混→压片→包衣→内包装→外包→入库。
本保健食品可用于调节免疫功能,增加机体抵抗力,缓解疲劳,恢复精力。
本保健食品应用于纠正免疫功能低下或过高,使得机体免疫功能恢复正常;所述纠正免疫功能异常为提供机体非特异性免疫和特异性免疫功能,就此免疫功能偏低或过高引起的机体不适。
以下为本保健品的主要成分。
人参(Panax ginseng)
人参,又称为亚洲参,在中国东北土名“棒槌”,是具有肉质的根,可药用。人参属于五加科,主要生长在东亚,特别是寒冷地区。人参是亚洲常见药材,北中美洲也普遍使用花旗参。
人参之所以很稀奇,很名贵,主要与它的药用价值有关。在很早的医书《神农本草经》中就认为,人参有“补五脏、安精神、定魂魄、止惊悸、除邪气、明日开心益智”的功效,“久服轻身延年”。李时珍在《本草纲目》中也对人参极为推崇,认为它能"治男妇一切虚症"。
人参可以分离出30余种人参皂甙,另外,人参还含有多种有机酸及酯类、各种维生素、甾醇、酶和20多种微量元素。
日常生活中,人参及其制备常常用于愈后恢复、增强体力、调节荷尔蒙、降低血糖和控制血压、控制肝指数和肝功能保健等。
灵芝孢子Ganoderma spore)
灵芝孢子粉是灵芝在生长成熟期,从灵芝菌褶中弹射出来的极其微小的卵形生殖细胞即灵芝的种子。每个灵芝孢子只有4-6个微米,是活体生物体,双壁结构,外被坚硬的几丁质纤维素所包围,人体很难充分吸收。破壁后更适合人体肠胃直接吸收。它凝聚了是灵芝的精华,具有灵芝的全部遗传物质和保健作用。
灵芝孢子的主要成分包括灵芝多糖,三萜类灵芝酸,天然有机锗,腺嘌呤核苷和微量元素硒。
北虫草(cordyceps militaris)
北虫草又名蛹虫草,于1958年在吉林省首次发现,通过鉴定,认为它与冬虫夏草是同一个属,主产于云南(昆明、安宁、江川)、吉林(安图、永吉)、辽宁(沈阳)、内蒙古(哲里木盟),生于针、阔叶林或混交林地表土层中鳞翅目昆虫的蛹体上。能采用家蚕和柞蚕蛹人工批量培育,药效、药理与野生种相似甚至更好。
北虫草较之冬虫夏草,具有几个无可比拟的优点:
1.一是北虫草为虫草属的模式种,分布广泛,为世界各国学者所认识和接受。
2.二是北虫草已在人工条件下育成了完整子座。
3.三是北虫草含有虫草菌素和虫草多糖,其独特药理作用已日益引起药学界的高度重视。
事实上,在一般情况下,特定的生物体有特定的生物化学反应,特定的生物化学反应才能产生特定的生物物质。就冬虫夏草而言,各种营养成分只有通过冬虫夏草菌的生物体吸收、合成的生物化学作用,才能同时形成虫草素、虫草酸和虫草多糖等多种生物活性物质,其他生物方法或人工化学方法是不能同时达到的。人工化学方法能够合成其中的一种而难以同时合成多种。冬虫夏草菌是一种生物反应器,不管使用什么方法生产,其合成的生物活性物质是一样的。这些生物活性物质的保健和药用价值相同。虫草素、虫草酸和虫草多糖是冬虫夏草菌特有的物质,是冬虫夏草特殊功效的主要指标。而恰恰是这些指标,在人工环境优裕条件下生长的北冬虫夏草含量可以比天然条件下生长得更高。人工培养的北冬虫夏草的蛋白质、氨基酸、维生素等含量均达到或超过天然冬虫夏草的水平。
银杏(Ginkgo biloba L.)
银杏是一种具有很高药用价值的植物,银杏树是我国古老的树种,它是神奇的医疗之树,2亿5千多年前侏罗纪恐龙掌控地球时,银杏已经是最繁盛的植物之一。地球生命历经千亿年的变动,尤其是第四世纪冰川覆盖之后,只有银杏仍保持它最原始的面貌,在生物演化学史上被称为“活化石”。其叶、果实、种子均有较高的药用价值,其药理作用不断被认识,临床应用范围逐步扩大。
近年来中国科学院和国内外众多医学专家研究发现:银杏叶中可提取160多种有效的药用成分.其中,黄酮类化合物35种;17种氨基酸和多种微量元素.
银杏具有抗衰老,提高机体免疫力,增强人体抵抗力等多种功能。
肉桂(Cortex Cinnamomi Cassiae)
肉桂为樟科植物肉桂和大叶清化桂的干皮和枝皮。肉桂常绿乔木,生于常绿阔叶林中,但多为栽培。我国福建、台湾、广东、广西、云南等地的热带及亚热带地区均有栽培,尤以广西栽培为多,大多为人工纯林。
肉桂的功效与作用,肉桂味辛甘、性热,入肾、脾、膀胱经;有补元阳,暖脾胃,除积冷,通脉止痛和止泻的功效;主治命门火衰、肢冷脉微、亡阳虚脱、腹痛泄泻、寒疝、腰膝冷痛、阴疽流注、虚阳浮越之上热下寒等症。
黄精(Polygonatum sibiricum Delar.ex Redonte)
黄精是百合科植物黄精、多花黄精和滇黄精的根茎,属于补益类传统延缓衰老本保健食品。本品味甘性平无毒,归肺脾肾三经,功能滋阴润肺、补脾益气、滋肾填精。
黄精含有多种甾体皂、黄精多糖、洋地黄糖以及少量葱类化合物等,具有延长家蚕生存期、对抗自由基损伤、增强免疫功能,调节第二信使环磷酸腺(cAMP)水平、增强心肌收缩力、增强冠状动脉血流量、降血糖、降血脂、抗菌、抗病毒、抗幅射、抗突变、调节免疫功能等作用。是一种有很好开发前景的中药。
刺蒺藜(Tribulus terrestris L.)
为蒺藜科一年或多年生草本植物蒺藜的果实,主要产于东北、华北、及西北等地。刺蒺藜含脂肪油、挥发油、鞣质、树脂、甾醇、钾盐、微量生物碱、皂甙等。其水提物、乙醇浸出液对麻醉动物均有降压作用;蒺藜茎叶粗皂甙对小鼠遭受高温、低温、缺氧及游泳应激刺激均有明显保护作用:并能显着降低大鼠肾上腺内维生素C(Vc)含量,也能抑制大剂量氢化可的松引起的耗竭现象发生,对ACTH引起的Vc含量下降起保护作用。切除小鼠双侧肾上腺后,其耐缺氧作用不再复现。这些作用可能与肾上腺皮质有关,调节其功能免遭耗竭可能是实现强壮的途径之一。Tribesta(蒺藜地上部分制成的制剂)给予雄性大鼠口服可明显刺激精子形成,兴奋赛托利细胞(Sertolicell)活性,增加性欲;给予雌性大鼠则能促进发情,提高生殖力。
秋葵(Hibiscus esculentus L.)
秋葵的别名有咖啡黄葵、黄秋葵、毛茄等。原产于非洲,20世纪初由印度引入我国。它的可食用部分是果荚,脆嫩多汁,滑润不腻,香味独特,深受人们青睐。
秋葵嫩果中含有一种黏性液质及阿拉伯聚糖、半乳聚糖、鼠李聚糖、蛋白质等,经常食用帮助消化、增强体力、保护肝脏、健胃整肠。秋葵含有铁、钙及糖类等多种营养成分,有预防贫血的效果。秋葵含有维生素A和β—胡萝卜素等,有益于视网膜健康、维护视力;其中富含有锌和硒等微量元素,能增强人体防癌、抗癌。秋葵中的黏蛋白有抑制糖吸收的作用,所以近年来又作为治疗糖尿病的偏方。秋葵还含有特殊的具有药效的成分,能强肾补虚,对男性器质性疾病有辅助治疗作用,享有“植物伟哥”之美誉。
玛咖(Maca)
玛咖(Lepidium meyemii Walp),是十字花科独行菜属一年生或两年生草本植物,原产秘鲁中部海拔4000m以上的安第斯山区。由于Maca耐低温、大风,能在恶劣的生态条件下生长,成为当地主要作物之一。主要食用部位是根,地下膨大的贮藏根直径2~5cm,表面颜色大多为黄色或紫色,肉质白色或淡黄色,具有刺激性气味和特殊的咸味奶油糖果气味。目前,玛咖的高产地(栽培品为主)仍在安第斯山脉卡华玛沃地区(Carhuamayo)和胡宁区(Junin)。引种至秘鲁其他地区或国外德国、捷克等地的情况不佳,发育不良未获得满意的结果。玛咖适宜生长地为海拔4000~4500m的高寒、强风及高日照地区。
玛咖(Maca)是药食兼用的植物,特产于南美洲秘鲁,当地印加人将其用做,补药,称其为秘鲁人参。在南美秘鲁等地,玛咖根鲜用时可与肉或其它蔬菜一起炒熟食用,晒干后则用水或牛奶煮熟即可食用,数千年来,玛咖根作为食物和草药用于增强精力,调节免疫功能,改善性功能,提高生育力,治疗女性更年期综合征等。
实验
1材料与方法
1.1样品:
1.2实验动物:昆明种及ICR小鼠,体重18~22g,雌雄各半,由中国药科大学实验动物室提供。。
1.3仪器与试剂:游泳箱、铅丝、全波长酶标仪、恒温水浴箱、离心机、印度墨汁(Black Indian Ink):北京西中化工厂产品,使用前用生理盐水稀释3倍,超声处理后离心,弃去沉淀物;二硝基氟苯(Dini-trofluorobenzene,DNFB):吴江市青云精细化工厂产品,使用前配成1%DNFB溶液,称取DNFB 50mg,溶于预先配好的丙酮麻油溶液(丙酮一麻油1:1)5ml中。羊红细胞购自南京医科大学,临用前用生理盐水配制成20%SRBC。都氏试剂:分析纯碳酸氢钠1.0g.风向纯高铁氰化钾0.2g,分析纯氰化钾0.05g,用蒸馏水溶解至1000ml。
1.4实验方法:
1.4.1对非特异性免疫功能的影响——碳粒廓清法
将昆明种小鼠随机分为5组,每组10只,小剂量组灌胃400mg/kg的本保健食品,中剂量灌胃800mg/kg的本保健食品,大剂量灌1600mg/kg的本保健食品。阳性对照组给予云芝多糖(Polysaccharide from Coriot“versicolor,PCV)1000mg/kg,阴性对照组给予等量0.9%生理盐水,上述各组均灌胃给药,每日1次,连续7d。第7天给药后0.5h,各鼠尾静脉注射经稀释的印度墨汁0.05ml/10g,于1(t1)和5(t5))min后,分别从眼眶静脉取血20ul,加到0.1%Na2CO3溶液2m1中摇匀,用分光光度计在680nm波长下比色,测定t1和t5的光密度(OD1和0D5),计算廓清指数K和吞噬指数α。之后,将小鼠放血处死,取肝脏、脾脏及胸腺称重,计算其脏器系数。廓清指数K=(1ogOD1一logOD5)/(t5一t1)=log(0D1/0D5)/4;
吞噬指数α=体重/肝脾重×K1/3;脏器系数=器官重量/体重
1.4.2对特异性细胞免疫功能的影响
采用二硝基氟苯诱导小鼠迟发型变态反应试验法(DTH),将ICR小鼠分组及剂量设置同前,上述各组均灌胃给药,每日1次,连续7d。每鼠腹部去毛,范围为3cm×3cm。将1%DNFB均匀涂抹于上,DNFB为一种半抗原,与皮肤蛋白结台成全抗原后可刺激T淋巴细胞增殖成致敏淋巴细胞。末次给药后0.5h,将1%DNFB均匀涂抹于小鼠右耳,使局部产生迟发型变态反应(水肿),24h后,脱颈椎处死小鼠,剪下左右耳壳。用打孔器取下直径8mm的耳片。称重,以左右耳片重量之差作为肿胀度,比较各组的差别。
1.4.3对特异性体液免疫功能的影响——血清溶血素测定法
ICR小鼠分组及剂量设置同前,上述各组均灌胃给药,每日1次,连续4d。给药第l天小鼠Ip 20%SRBC 0 2ml/只,免疫后第4天摘眼球取血,分离血清.将血清稀释500倍后供测定。反应管内依次加人经稀释的血清l ml,5%SRBC 0 5ml,l0%补体1ml,置于37℃恒温水浴中保温30min,然后移至冰浴中终止反应,1500r/min离心5min,取上清液l mI加都氏试剂3m1,摇匀放置10min,于540m波长处比色读取吸光度。测定SRBC半数溶血值:取5%SRBC025ml加都氏试剂至4ml,比色读取吸光度值。计算血清HC50=样品的吸光度值/SRBC半数溶血值×稀释倍数。
实验数据:
2结果
2.1对非特异性免疫功能的影响——碳粒廓清法
表1和表2表示调节免疫功能本保健食品对小鼠对非特异性免疫功能的影响。其中表1为本保健食品对小鼠廓清指数K和吞噬指数α影响的实验结果;表2为本保健食品对小鼠脾脏和胸腺重量影响的实验结果。从表1可以看出,与对照组相比,阳性对照组和口服给予本发明所述的调节免疫功能本保健食品后小鼠碳粒廓清指数和吞噬指数呈现剂量依赖性延长,经方差分析,各剂量组与对照组相比有显著性差异(p<0.05-0.01)。
表2结果表明,与对照组相比,阳性组和口服给予调节免疫功能本保健食品后,各剂量组小鼠脾脏脏器的重量均显著增加;中等和大剂量给药组胸腺的重量显著增加,与对照组差异达显著水平(表2),具有统计学意义(p<0.05-0.01)。上述结果显示,本保健品可以显著增强非特异性免疫功能。
2.2对特异性免疫功能的影响
表3和表4为调节免疫功能本保健食品对特异性免疫功能的影响。其中表3为保健食品二硝基对氟苯诱导的小鼠耳廓肿胀的影响的实验结果,表4为本保健食品对溶血素水平影响的实验结果。从表3可以看出,和对照组相比,本保健品大、小剂量组具有显著地增加小鼠耳肿胀度作用且呈剂量依赖性(P<0 01)。说明本保健品具有一定的增强二硝基氟苯诱导的小鼠迟发性变态反应作用。从表4可以看出,用血清溶血素测定法分析本保健食品对特异性免疫功能的影响结果显示口服给予本保健食品后,与对照组比较,各用药组可显著地提高小鼠溶血素水平(P<0 05-0 01),并呈剂量依赖性(表4),说明本保健品具有一定的增强特异性体液免疫的作用。
综合上述实验结果,本发明提供的这种调节免疫功能本保健食品能明显增加小鼠脾脏、胸腺的重量;提高小鼠碳粒廓清指数和吞噬指数;增强小鼠局部迟发性变态反应以及增加小鼠溶血素水平,提示本发明具有明显的调节免疫功能作用。
本发明经动物实验证实本保健食品对免疫有明显的调节作用,具有无毒性,安全,可口服,可食用等优点。
本发明发现本保健食品在调节免疫功能的功能检验方法实验中呈阳性,结果表明本保健品有增强单核巨噬细胞吞噬功能的作用,并有显著地增强特异性细胞免疫及体液免疫的作用,本保健品对非特异性和特异性免疫功能均有显著的提高作用,且具有用量小、安全、可注射、可口服等优点,具有较大的保健和临床应用价值。本发明提供的这种调节免疫功能可应用于制备调节免疫功能保健品或食品。
本保健食品调节免疫功能的具体研究,对于确认其调节免疫功能以及其保健功能有现实意义和应用价值。
本发明的优点是:
1.安全,无毒性,可口服。
2.对本保健食品中的主要原材料的功能做了新的探索,在其原知功能基础上做了很好补充,发现其调节免疫功能作用。
3.本保健食品口服或食用方便,有显著调节免疫功能保健功能,推荐人用剂量约为玛咖每天不超25克(60kg.BW),人参每天用量不超过3克(60kg.BW)。
具体实施方式
下面结合实施例对本发明作进一步说明。
实施例1:
一种调节免疫功能的保健食品,按重量份数配制以下组分:
(秋葵提取物:为淡黄色粉末,由黄秋葵的根、叶、花和种子混合、粉碎后提取。主要提取工艺:清水洗净→加开水碎浆→滤除残渣→浓缩干燥。提取物有效成份的浓度为10%)。
黄精: 4份;
银杏提取物: 1份;
(银杏提取物:为浅棕黄色至棕褐色的粉末。是以银杏Ginkgo biloba L.的叶为原料,采用适当的溶剂,提取的有效成分提取物。主要生产工艺流程为:银杏叶→清水洗净等前处理→醇提→回收浓缩→精制→喷雾干燥。提取物有效成份浓度为20%)。
刺蒺藜提取物:2份;(刺蒺藜提取物:为棕黄色粉末,主要生产工艺流程为:刺蒺藜原料→粉碎→醇提→浓缩→萃取→干燥。其中皂甙含量为40%)。
肉桂提取物:3份。(肉桂提取物:为黄棕色粉末,主要从樟科植物肉桂Cinnamomumcassia Presl的树皮中获得的提取物。主要生产工艺流程为:选材→煎煮→渗漉→回流→蒸馏→沉淀→静置→过滤→浓缩→干燥。提取物有效成份含量为15%)。
加2份药用辅料微晶纤维素和1份药用辅料硬脂酸镁,制作为片剂。
然后将原辅料粉碎过筛→预混→制粒干燥→整粒→总混→压片→包衣→内包装→外包→入库。
根据每日1~2次,每次1000-3000mg/60kg体重的用量,还可以生产为口服液、饮料、胶囊、喷雾剂或透皮吸收剂。
实施例2:
一种调节免疫功能的保健食品,按重量份数配制以下组分:
秋葵提取物: 12份;
(秋葵提取物:为淡黄色粉末,由黄秋葵的根、叶、花和种子混合、粉碎后提取。主要提取工艺:清水洗净→加开水碎浆→滤除残渣→浓缩干燥。提取物有效成份的浓度为10%)。
黄精: 10份;
银杏提取物:3份;(银杏提取物:为浅棕黄色至棕褐色的粉末。是以银杏Ginkgobiloba L.的叶为原料,采用适当的溶剂,提取的有效成分提取物。主要生产工艺流程为:银杏叶→清水洗净等前处理→醇提→回收浓缩→精制→喷雾干燥。提取物有效成份浓度为20%)。
刺蒺藜提取物:6份;(刺蒺藜提取物:为棕黄色粉末,主要生产工艺流程为:刺蒺藜原料→粉碎→醇提→浓缩→萃取→干燥。其中皂甙含量为40%)。
肉桂提取物: 7份。
(肉桂提取物:为黄棕色粉末,主要从樟科植物肉桂Cinnamomum cassia Presl的树皮中获得的提取物。主要生产工艺流程为:选材→煎煮→渗漉→回流→蒸馏→沉淀→静置→过滤→浓缩→干燥。提取物有效成份含量为15%)。
加2份药用辅料微晶纤维素和1份药用辅料硬脂酸镁,制作为片剂。
然后将原辅料粉碎过筛→预混→制粒干燥→整粒→总混→压片→包衣→内包装→外包→入库。
根据每日1~2次,每次1000-3000mg/60kg体重的用量,还可以生产为口服液、饮料、胶囊、喷雾剂或透皮吸收剂。
实施例3:
一种调节免疫功能的保健食品,按重量份数配制以下组分:
秋葵提取物:8份;秋葵提取物:12份;(秋葵提取物:为淡黄色粉末,由黄秋葵的根、叶、花和种子混合、粉碎后提取。主要提取工艺:清水洗净→加开水碎浆→滤除残渣→浓缩干燥。提取物有效成份的浓度为10%)。
黄精: 7份;
银杏提取物: 2份;
(银杏提取物:为浅棕黄色至棕褐色的粉末。是以银杏Ginkgo biloba L.的叶为原料,采用适当的溶剂,提取的有效成分提取物。主要生产工艺流程为:银杏叶→清水洗净等前处理→醇提→回收浓缩→精制→喷雾干燥。提取物有效成份浓度为20%)。
刺蒺藜提取物:4份;(刺蒺藜提取物:为棕黄色粉末,主要生产工艺流程为:刺蒺藜原料→粉碎→醇提→浓缩→萃取→干燥。其中皂甙含量为40%)。
肉桂提取物: 5份。
(肉桂提取物:为黄棕色粉末,主要从樟科植物肉桂Cinnamomum cassia Presl的树皮中获得的提取物。主要生产工艺流程为:选材→煎煮→渗漉→回流→蒸馏→沉淀→静置→过滤→浓缩→干燥。提取物有效成份含量为15%)。
加2份药用辅料微晶纤维素和1份药用辅料硬脂酸镁,制作为片剂。
然后将原辅料粉碎过筛→预混→制粒干燥→整粒→总混→压片→包衣→内包装→外包→入库。
根据每日1~2次,每次1000-3000mg/60kg体重的用量,还可以生产为口服液、饮料、胶囊、喷雾剂或透皮吸收剂。
最后需要说明的是,上述描述仅仅为本发明的优选实施例,本领域的普通技术人员在本发明的启示下,在不违背本发明宗旨及权利要求的前提下,可以做出多种类似的表示,这样的变换均落入本发明的保护范围之内。
Claims (4)
1.一种调节免疫功能的保健食品,按重量份数包含以下组分:
2.根据权利要求1所述一种调节免疫功能的保健食品,其特征在于:所述保健食品还添加有药用辅料。
3.根据权利要求1所述一种调节免疫功能的保健食品,其特征在于:所述保健食品为口服液、饮料、片剂、胶囊、喷雾剂或透皮吸收剂。
4.一种如权利要求1-2所述一种调节免疫功能的保健食品的制备方法,按如下步骤进行:原辅料粉碎过筛→预混→制粒干燥→整粒→总混→压片→包衣→内包装→外包→入库。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710253682.0A CN107006857A (zh) | 2017-04-18 | 2017-04-18 | 一种调节免疫功能的保健食品及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710253682.0A CN107006857A (zh) | 2017-04-18 | 2017-04-18 | 一种调节免疫功能的保健食品及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107006857A true CN107006857A (zh) | 2017-08-04 |
Family
ID=59447323
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710253682.0A Pending CN107006857A (zh) | 2017-04-18 | 2017-04-18 | 一种调节免疫功能的保健食品及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107006857A (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103169079A (zh) * | 2013-03-04 | 2013-06-26 | 无锡市天赐康生物科技有限公司 | 一种具有抗疲劳、增强免疫力作用的保健食品及其制备方法 |
CN104257748A (zh) * | 2014-09-05 | 2015-01-07 | 洛阳华以生物工程有限公司 | 一种保健品配方 |
CN104694357A (zh) * | 2015-03-20 | 2015-06-10 | 吉林大学 | 增强免疫力人参保健酒及其制备方法 |
CN104739977A (zh) * | 2015-02-27 | 2015-07-01 | 苟春虎 | 玛咖养生壮元酒(片) |
CN105394511A (zh) * | 2015-12-04 | 2016-03-16 | 广东红珊瑚药业有限公司 | 一种具有增强免疫力作用的含玛咖速溶冲剂及其制备方法 |
CN105560320A (zh) * | 2016-01-20 | 2016-05-11 | 南京扶元固本堂生物科技有限公司 | 一种人参灵芝蛹虫草粉配方及制备方法 |
CN106420886A (zh) * | 2015-08-07 | 2017-02-22 | 珠海宝德润生健康科技有限公司 | 一种具有缓解体力疲劳、增强免疫力功能的组合物及其制备方法 |
-
2017
- 2017-04-18 CN CN201710253682.0A patent/CN107006857A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103169079A (zh) * | 2013-03-04 | 2013-06-26 | 无锡市天赐康生物科技有限公司 | 一种具有抗疲劳、增强免疫力作用的保健食品及其制备方法 |
CN104257748A (zh) * | 2014-09-05 | 2015-01-07 | 洛阳华以生物工程有限公司 | 一种保健品配方 |
CN104739977A (zh) * | 2015-02-27 | 2015-07-01 | 苟春虎 | 玛咖养生壮元酒(片) |
CN104694357A (zh) * | 2015-03-20 | 2015-06-10 | 吉林大学 | 增强免疫力人参保健酒及其制备方法 |
CN106420886A (zh) * | 2015-08-07 | 2017-02-22 | 珠海宝德润生健康科技有限公司 | 一种具有缓解体力疲劳、增强免疫力功能的组合物及其制备方法 |
CN105394511A (zh) * | 2015-12-04 | 2016-03-16 | 广东红珊瑚药业有限公司 | 一种具有增强免疫力作用的含玛咖速溶冲剂及其制备方法 |
CN105560320A (zh) * | 2016-01-20 | 2016-05-11 | 南京扶元固本堂生物科技有限公司 | 一种人参灵芝蛹虫草粉配方及制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hobbs | Medicinal mushrooms: an exploration of tradition, healing, and culture | |
CN103992924B (zh) | 增强机体免疫力的保健露酒及其制作方法 | |
CN100374538C (zh) | 五脏滋补酒及其制备工艺 | |
CN102827750A (zh) | 一种具有提高机体免疫力及性活力的玛咖保健酒 | |
CN104719535A (zh) | 一种改善女性亚健康状态的玛卡黑茶组合物及制备方法 | |
CN101518336A (zh) | 一种具有抗氧化功能的营养食品及其制备方法 | |
CN102669362A (zh) | 一种增强免疫力的苦荞茶及其加工方法 | |
CN108524814A (zh) | 一种用于降低血糖的中药组合物及其制备方法 | |
CN106615431A (zh) | 一种菊芋片茶及其制作方法 | |
CN106244371A (zh) | 一种降血糖黄精葡萄保健酒及其生产工艺 | |
CN104719536A (zh) | 一种改善男性亚健康状态的玛卡黑茶组合物及制备方法 | |
CN107048386A (zh) | 一种性功能调节保健食品 | |
CN103875973B (zh) | 一种蛋鸡产蛋期饲料添加剂及其制备方法 | |
CN103301413A (zh) | 一种治疗高血脂合并高血糖症的中药组合物 | |
CN107751993A (zh) | 一种抗疲劳膏滋及其制备方法 | |
CN103155985B (zh) | 一种黄精营养粉及其制备方法 | |
CN106177053A (zh) | 一种包含青钱柳叶和陈皮的降血糖保健组合物 | |
CN110367522A (zh) | 一种用于增强免疫力的药膳组合物及其制备方法 | |
CN106722437A (zh) | 一种用于保护肝脏的含硒制品及其制备方法和应用 | |
CN109481589A (zh) | 一种治疗肺癌的排毒抗癌胶囊及食疗抗癌的制备方法 | |
CN103462020A (zh) | 一种可抑制重金属和农药残留危害的天然营养素 | |
CN106177477A (zh) | 一种用于降血糖、降血脂和降血压的保健组合物 | |
CN104489172A (zh) | 一种提高免疫力的刺五加保健茶及其制备方法 | |
CN100442997C (zh) | 龟斛胶 | |
CN102090637A (zh) | 一种含有胶原蛋白的复方营养粉 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170804 |